Report
Ingird Gafanhão

TRAVERE THERAPEUTICS - SELL | USD17 Sparsentan PDUFA delayed as FDA places safety concerns on the spotlight

Detail on the delay
Safety focus should impact sales uptake
Underlying
TRAVERE THERAPEUTICS

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Ingird Gafanhão

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch